

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**212690Orig1s000**

**CLINICAL PHARMACOLOGY**  
**REVIEW(S)**

---

# Office of Clinical Pharmacology

## Integrated Clinical Pharmacology Review

---

NDA Number	212690 Sequence Number 0001
Link to EDR	<a href="\\CDSESUB1\evsprod\NDA212690\212690.enx">\\CDSESUB1\evsprod\NDA212690\212690.enx</a>
Submission Date	01/21/2020
Submission Type	505(b)(1) Application – Priority review
Brand Name	XYWAV™
Generic Name	JZP-258
Dosage Form and Strength	Solution (0.5 g/ml), for oral administration
Proposed Indication	Treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy
Proposed Dose/regimen	<p><u>Adults:</u></p> <p>Initiate dosage at 4.5 g per night orally divided into two equal doses taken 2.5 to 4 hours apart</p> <ul style="list-style-type: none"><li>• Titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later).</li><li>• Recommended dosage range: 6 to 9 g per night orally.</li></ul> <p><u>Pediatric patients</u> (7 years of age and older)</p> <p>The recommended starting dosage, titration regimen and maximum total nightly dosage are based on body weight</p>
Applicant	Jazz Pharmaceuticals Ireland Limited.
Associated IND	49641
OCP Review Team	Gopichand Gottipati Ph.D., Atul Bhattaram, Ph.D., Sreedharan Sabarinath, Ph.D.
OCP Final Signatory	Mehul Mehta, Ph.D.

---

## Table of Contents

Table of Contents .....	2
List of Abbreviations .....	3
1 Executive Summary .....	4
1.1 Recommendations .....	4
1.2 Post-marketing Requirements .....	7
2 Summary of Clinical Pharmacology Assessment .....	7
2.1 The Pharmacology and Clinical Pharmacokinetics .....	7
2.2 Dosing and Therapeutic Individualization .....	9
2.2.1 General dosing .....	9
2.2.2 Therapeutic individualization .....	9
2.2.3 Outstanding Issues .....	9
2.2.4 Summary of Labeling Recommendations .....	9
3 Comprehensive Clinical Pharmacology Review .....	10
3.1 Overview of the Product and Regulatory Background .....	10
3.2 General Pharmacological and Pharmacokinetic Characteristics .....	11
3.3 Clinical Pharmacology Questions .....	12
3.3.1 To what extent does the available clinical pharmacology information provide pivotal or supportive evidence of effectiveness? .....	12
3.3.2 Is the proposed dosing regimen appropriate for the general population for which the indication is being sought? .....	13
3.3.3 Is an alternative dosing regimen and management strategy required for subpopulations based on intrinsic/extrinsic factors? .....	14
3.3.4 Are there clinically relevant food-drug or drug-drug interactions and what is the appropriate management strategy? .....	14
3.3.5 Is the to-be-marketed formulation the same as the clinical trial formulation, and if not, are there bioequivalence data to support approval of the to-be-marketed formulation? .....	19
4 APPENDICES .....	20
4.1 Summary of Bioanalytical Method Validation .....	20
4.2 Pharmacometrics Assessment: Population PK Analyses .....	21
4.2.1 Applicant's Population PK analysis: .....	21
4.2.2 Applicant's Exposure-Efficacy Analyses .....	28
4.2.3 Reviewer's Exposure-Response Analyses: .....	34

## List of Abbreviations

AE	Adverse event
AUC	Area under the concentration-time curve
AUCinf	AUC from time 0 to extrapolated to infinity
AUClast	AUC from time 0 to last measurable concentration
CI	Confidence intervals
Cmax	Maximum (peak) drug concentration
FDA	Food and drug administration
LLOQ	Lower limit of quantification
NDA	New Drug Application
PK	Pharmacokinetics
Tmax	Time of maximum (peak) drug concentration
USPI	United States package insert

## 1 Executive Summary

Jazz Pharmaceuticals Ireland Limited submitted this original 505(b)(1) New Drug Application (NDA 212690) seeking approval for XYWAV™ (JZP-258) for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. JZP-258 is a 0.5 g/mL aqueous solution of mixture of calcium, potassium, magnesium, and sodium salts of oxybate; equivalent to 0.413 g/mL oxybate. Xyrem® (sodium oxybate) oral solution (also marketed by the same applicant) was approved by the Food and Drug Administration (FDA) for the treatment of cataplexy in narcolepsy (07/17/2002) and excessive daytime sleepiness (11/18/2005) in adults, and subsequently in pediatric patients 7 years and above for both indications (10/26/2018).

The proposed adult JZP-258 dosing recommendations are to initiate JZP-258 at 4.5 g per night orally in two equally divided doses taken 2.5 to 4 hours apart, and titrate to effect in increments of 1.5 g per night at weekly intervals (0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later), not exceeding total nightly dose of 9 g. The proposed JZP-258 pediatric dosing recommendations for initiation, titration regimen and maximum total nightly dosage are based on body weight. These recommendations are identical to those included in US package insert (USPI) for Xyrem®<sup>1</sup>.

The application package includes two relative bioavailability/bioequivalence studies, 13-010 and JZP258-101, in healthy subjects comparing JZP-258 with Xyrem® and a phase 3 double-blind, placebo-controlled randomized withdrawal study (15-006) in adult patients with narcolepsy. In addition, population PK and exposure-response analyses were included in this submission. This NDA relies on the approved product Xyrem (also from the same applicant) for dosing recommendations for intrinsic and extrinsic factors.

The primary focus of this review is to evaluate the dosing recommendations for JZP-258 with regards to food-intake.

### 1.1 Recommendations

The Office of Clinical Pharmacology (OCP) recommends the approval of JZP-258 for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adult and pediatric populations at doses listed below. (b) (4)

The first dose of JZP-258 should be administered at least 2 hours after meals, just as it is recommended in the USPI for Xyrem.

Key review issues with specific recommendations and comments are summarized below.

---

<sup>1</sup> USPI for Xyrem accessed at: [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2018/021196s030lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021196s030lbl.pdf)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.